Replimune Has Been Selling TUDRIQEV for 20 Days and Still Won't Count Its Patients

For eleven years Replimune was a science project with a burn rate. On this call it became a company with a price list. The fiscal second quarter contains no product revenue at all — first shipments of TUDRIQEV went out in early October, days after the September 30 close — so the entire earnings release is a timing artifact. What matters is everything management said after the numbers: 20 business days into launch, more than 15 institutions have written prescriptions, roughly 20 accounts have put the drug on formulary, and over 70% of the initial 200 target accounts have been engaged.

The Funnel Is the Disclosure

The most revealing moment on the call was not a milestone, it was an excuse. Asked repeatedly for patient counts and per-patient revenue, the company declined — and the reason is structural, not evasive. Dosing is volume-based, roughly one milliliter per centimeter of lesion, so a script is not a patient and a shipment is not a course.

As you know, TUDRIQEV treatment is based on a patient volume with about 1 ml per centimeter used for patients. So as we see these initial robust orders come in, it is difficult for us to track the exact patient numbers.

Instead, Replimune has substituted a patient numbers-free scoreboard: engagement, formulary placement, and first scripts. It is honest, and it is also convenient — every one of those metrics can improve while revenue stays small. Management was explicit that a single patient's course "runs over several months" and that revenue "may be recognized over more than 1 quarter," which means the fiscal third quarter will understate demand no matter how strong it is. Investors expecting a clean launch curve should prepare for a lumpy one.

What they will get instead is a price anchor: $450,000 per course before rebates, against roughly 10,000 addressable U.S. patients and about 8,500 annual melanoma deaths. Michelle DiNapoli framed the launch as a funnel in her prepared remarks, and the numbers inside it are genuinely fast for a drug with a broad label and a miscellaneous billing code. Moffitt and Memorial Sloan Kettering are named as already treating. More striking is the workaround behavior: “other sites have told us that they are expediting and in some cases, bypassing the usual formulary review to get TUDRIQEV to patients without delay.” — Michelle DiNapoli · 2026-10-28 Sites do not bypass their own pharmacy committee for a therapy they are lukewarm about.

Access Got Solved First — That Is the Real News

The bear case for any first-launch oncology asset is reimbursement drift: a permanent J-code years away, payers hiding behind prior authorization, and a slow bleed into 2028. Replimune appears to have pre-empted it. The drug landed as an NCCN Category 2A recommendation, Medicare coverage is established, and — the key claim — many commercial payers have already published policies written to label.

Two details carry the argument. First, published policies reportedly permit retreatment where clinically appropriate, with no volume caps; DiNapoli noted some policies allow up to 24 doses against a label of eight plus retreatment. Second, the company is operating on a miscellaneous J code until roughly April 2027, and still got major national and regional payers to publish. That sequencing is unusual. Normally the code comes first and the policies follow.

The honest caveat is that all of this is early-adopter behavior at academic centers with existing intratumoral experience and interventional radiology on staff. DiNapoli conceded the first 15 accounts are "mostly within our expectations" — hospital-based, trial-experienced, comfortable with a miscellaneous code. The upside surprise was a handful of regional centers adopting quickly. The strategic pivot that matters is the explicit embrace of interventional radiologists as a prescribing-adjacent stakeholder; Sushil Patel called image-guided delivery "a big focus of ours" and said image guided injections are already happening in the opening weeks. Blocks of 200 accounts covering roughly 30% of U.S. melanoma patients, then a next wave of 250 adding another 20%, is the roadmap — and management hinted it may pull the second wave forward if the first keeps pace.

The Balance Sheet Pays for the Ambition

The quiet story in the P&L is the pivot from discovery to distribution. Research and development fell to $34.4 million from $49.3 million sequentially, while SG&A rose to $21.9 million from $19 million on field hiring and patient support. That is a deliberate reallocation, not distress: R&D of $49 million in the June quarter, down 15% year-over-year from a 2025 peak of $56 million.

Cash is the number that decides whether this launch gets to compound. The company ended September with $307.8 million, including $141 million of net proceeds from the August offering, up from $195.3 million at June 30, and guided to greater than 12 months of funding covering both the launch and the IGNYTE-3 confirmatory study. Without that raise the picture was tight — the filed balance sheet implied a cash runway of just 2.6 quarters. Leverage on the balance sheet has also climbed as manufacturing and lease obligations built out.

So the arithmetic is straightforward and unforgiving: roughly $56 million of quarterly operating spend against $308 million of cash buys about five quarters. That is enough to prove a trajectory, not enough to prove a market. The permanent J-code in April 2027 is the natural checkpoint — it is the gate to community oncology, where the bulk of the remaining 70% of melanoma patients sit.

What to Watch

Not the third-quarter revenue line, which will be a partial-course artifact. Watch three things instead: whether the account count roughly doubles by year-end as DiNapoli projected; whether the mix shifts from academic to regional and community sites; and whether the average volume per patient tracks the IGNYTE trial population, which management insists was representative of the real world. If real-world tumor burden comes in heavier than trial burden, the $450,000 list price is conservative; if lighter, the revenue per script disappoints.

The contrast with the broader market is worth noting. This quarter's global keyword tables are dominated by tariff refunds, Fed rate paths, and AI data center buildouts — macro and megacap themes with hundreds of tickers behind them. Replimune's entire vocabulary is brand new and entirely its own: TUDRIQEV, formulary, workflows, injections. There is no wave to ride here, which is precisely why the launch metrics matter more than the sector tape. A single-product company 20 days into its first sale is not a trend; it is a coin flip with unusually good disclosure.